Differences in the diagnosis and treatment of hematologic malignancies attributable to health insurance coverage.

Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE

Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins

Health Services Accessibility*/economics ; Health Services Accessibility*/statistics & numerical data ; National Health Programs*; Hematologic Neoplasms/*diagnosis ; Hematologic Neoplasms/*therapy ; Insurance Coverage/*statistics & numerical data ; Insurance, Health/*economics ; Insurance, Health/*statistics & numerical data; Age Factors ; Female ; Health Expenditures ; Hematologic Neoplasms/economics ; Humans ; Sex Factors

Abstract: Medical care should be equally provided to the public regardless of their financial capability. In the real world, expenditures directly out from the patient sector decide the medical journey, even in a country with national health insurance. The aim of this study was to investigate whether there are differences in the diagnostic and treatment processes in hematologic malignancies based on patient characteristics, such as health insurance status.Through the review of 5614 "CBCs with differential count" results with abnormal cells from 358 patients from January 2010 to June 2017, 238 patients without past medical histories of hematologic malignancies were enrolled. Excluding reactive cases, 206 patients with hematologic malignancy were classified into 8 disease categories: acute leukemia, myelodysplastic syndrome, myeloproliferative neoplasm (MPN), myelodysplastic syndrome/MPN, lymphoid neoplasm, plasma cell neoplasm, r/o hematologic malignancy, and cancer.The patients' age, sex, disease categories and follow-up durations showed associations with the clinical course. The "refusal of treatment" group was the oldest and had a relatively higher percentage of females, whereas those who decided to transfer to a tertiary hospital were younger. The age, clinical course, and follow-up durations were different across health insurance statuses. The medical aid group was the oldest, and the group whose status changed from a medical insurance subscriber to a medical aid beneficiary during treatment was the youngest. The majority of patients who refused treatment or wished to be transferred to a tertiary hospital were medical insurance subscribers. The percentage of patients who were treated in this secondary municipal hospital was higher in the medical-aid beneficiaries group than in the medical insurance group. Follow-up durations were longest in the status change group and shortest in the medical insurance group.Almost all medical aid beneficiaries with hematologic malignancies opted to continue treatment at this secondary/municipal hospitals, indicating that this category of medical institutions provides adequate levels and qualified healthcare services to those patients. The secondary municipal hospital provides qualified healthcare services for medical aid beneficiaries with hematologic malignancies.
Competing Interests: The authors have no funding and conflicts of interest to disclose.
(Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.)

Tefferi A, Hanson CA, Inwards DJ. How to interpret and pursue an abnormal complete blood cell count in adults. Mayo Clin Proc 2005;80:923–36.
Kim YG, Kwon JA, Moon Y, et al. An automated draft report generator for peripheral blood smear examinations based on complete blood count parameters. Ann Lab Med 2018;38:512–7.
Nakul-Aquaronne D, Sudaka-Sammarcelli I, Ferrero-Vacher C, Starck B, Bayle J. Evaluation of the Sysmex Xe-2100 hematology analyzer in hospital use. J Clin Lab Anal 2003;17:113–23.
Bersabe AR, Aden JK, Shumway NM, Osswald MB. Peripheral smear review and bone marrow biopsy correlation. J Clin Diagn Res 2017;11:JC01–3.
Korean Statistical Information Service. Life Expectancy at Birth (Korea), Data updated on: March 28, 2019. Available at: https://kosis.kr/statHtml/statHtml.do?orgId=101&tblId=DT_1BPA201&vw_cd=MT_ETITLE&list_id=A41_10&scrId=&seqNo=&language=en&obj_var_id=&itm_id=&conn_path=A6&path=%252Feng%252Fsearch%252FsearchList.do . Accessed: 22 October, 2020.
Bahk J, Kang HY, Khang YH. Trends in life expectancy among medical aid beneficiaries and national health insurance beneficiaries in Korea between 2004 and 2017. BMC Public Health 2019;19:1137.
Choi JW, Park EC, Chun SY, Han KT, Han E, Kim TH. Health care utilization and costs among medical-aid enrollees, the poor not enrolled in medical-aid, and the near poor in South Korea. Int J Equity Health 2015;14:128.
Weinkauff R, Estey EH, Starostik P, et al. Use of peripheral blood blasts vs bone marrow blasts for diagnosis of acute leukemia. Am J Clin Pathol 1999;111:733–40.
Park CH, Ahn KO, Shin SD, Park JH, Lee SY. Association between health insurance status and transfer of patients with return of spontaneous circulation after out-of-hospital cardiac arrest. Resuscitation 2020;149:143–9.

Date Created: 20220304 Date Completed: 20220322 Latest Revision: 20230103

20240105

PMC8896484

10.1097/MD.0000000000029020

35244084